Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.56
29
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Other Operating Expenses
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Other Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Z
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
|
Other Operating Expenses
¥17.9m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Operating Expenses
-¥64.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Other Operating Expenses
¥27.6m
|
CAGR 3-Years
80%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Operating Expenses
¥438.9m
|
CAGR 3-Years
24%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Other Operating Expenses
-¥60.6m
|
CAGR 3-Years
-74%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Other Operating Expenses
¥49.1m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Glance View
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. emerged on the healthcare scene in China with an unwavering focus on improving allergy treatments. Founded in 1992, the company has carved a niche in the bio-pharmaceutical industry by specializing in the research, development, and manufacturing of allergen-specific immunotherapeutic products. At its heart, Wolwo operates with a clear mission: to diminish the burden of allergic diseases. The company leverages cutting-edge bio-pharmaceutical technologies to produce allergen detection and treatment products, thereby offering innovative solutions to millions affected by allergic conditions. As allergies become more prevalent worldwide, Wolwo's focus on this segment positions it as a critical player in the healthcare market. Wolwo’s business model revolves around the development and commercialization of standardized allergen products. It generates revenue primarily from the sale of its patented therapeutic solutions targeting common allergens such as pollen, dust mites, and pet dander. This involves a deep dive into biotechnology, where their R&D teams continuously innovate to refine product offerings. The company has earned regulatory approvals across various regions, which significantly bolsters its revenue stream and expands its market footprint. Beyond just product sales, Wolwo actively engages in educational programs aimed at raising awareness about allergies, thus creating a well-rounded approach not only in tackling allergic diseases but also in ensuring long-term consumer loyalty and brand trust in a rapidly evolving market.
See Also
What is Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Other Operating Expenses?
Other Operating Expenses
17.9m
CNY
Based on the financial report for Sep 30, 2024, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Other Operating Expenses amounts to 17.9m CNY.
What is Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
48%
The average annual Other Operating Expenses growth rates for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd have been -11% over the past three years , 48% over the past five years .
You don't have any saved screeners yet
